Wait For Benefits Of EudraVigilance Pilot Before Expanding To More EU Products, Says Pharma
Executive Summary
Drug companies say that any decision on taking the EudraVigilance monitoring requirements into the next phase should only be made when there is clear evidence that it has improved patient safety.
You may also be interested in...
Pharma Disappointed By New Extension Of EU Signal Detection Pilot
A further extension of the EU signal detection pilot means that certain drug sponsors must keep monitoring the EudraVigilance database on a continuous basis. Industry argues there is enough evidence that this activity brings no additional value, and that current requirements should be replaced with a more proportionate approach.
EU Safety Signal Detection Pilot Extended Again
The pilot phase of a European project on new safety signal notification requirements has been extended for a second time following inconclusive results.
EU Getting Left Behind On Drug Review Times
Drug review times in the EU are not getting slower but other agencies are getting faster. A pharmaceutical industry representative offers some frank advice on how the EU can stay competitive.